Clinical variables and biomarkers according to whether TNFi was detectable in the patients’ blood following 6 months of treatment with adalimumab or infliximab.
IntroductionUndifferentiated arthritis (UA) represents an early and heterogeneous phase of inflammatory joint disease that may evolve into defined rheumatic conditions. This phase is characterized by
